4/2
08:12 pm
pyxs
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum [Yahoo! Finance]
Medium
Report
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum [Yahoo! Finance]
4/2
07:30 am
pyxs
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
High
Report
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
3/25
04:30 pm
pyxs
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
High
Report
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
3/19
10:45 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.
Low
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.
3/19
08:04 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/18
07:30 am
pyxs
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/3
07:30 am
pyxs
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Medium
Report
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
2/26
07:58 am
pyxs
Pyxis Oncology rises on FDA fast track tag for lead asset [Seeking Alpha]
High
Report
Pyxis Oncology rises on FDA fast track tag for lead asset [Seeking Alpha]
2/26
07:30 am
pyxs
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
High
Report
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
2/14
09:09 pm
pyxs
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 [Yahoo! Finance]
Low
Report
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 [Yahoo! Finance]
2/4
08:50 am
pyxs
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial [Yahoo! Finance]
Low
Report
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial [Yahoo! Finance]
2/4
07:30 am
pyxs
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Neutral
Report
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial